Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Ramelteon
- Accession Number
- DB00980 (APRD01213)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
- Structure
Structure for DB00980 (Ramelteon)
- Synonyms
- Not Available
- External IDs
- TAK-375 / TAK375
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Rozerem Tablet, film coated 8 mg/1 Oral Lake Erie Medical Dba Quality Care Produts Llc 2011-05-18 2017-09-20 US 
Rozerem Tablet, film coated 8 mg/1 Oral Rebel Distributors 2005-07-22 Not applicable US 
Rozerem Tablet, film coated 8 mg/1 Oral bryant ranch prepack 2005-07-22 Not applicable US Rozerem Tablet, film coated 8 mg/1 Oral Avera Mc Kennan Hospital 2015-03-05 Not applicable US Rozerem Tablet, film coated 8 mg/1 Oral Physicians Total Care, Inc. 2006-08-01 Not applicable US Rozerem Tablet, film coated 8 mg/1 Oral Carilion Materials Management 2005-07-22 Not applicable US Rozerem Tablet, film coated 8 mg/1 Oral Takeda 2005-07-22 Not applicable US - International/Other Brands
- Rozerem
- Categories
- UNII
- 901AS54I69
- CAS number
- 196597-26-9
- Weight
- Average: 259.3434
Monoisotopic: 259.157228921 - Chemical Formula
- C16H21NO2
- InChI Key
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N
- InChI
- InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
- IUPAC Name
- N-{2-[(8S)-1H,2H,6H,7H,8H-indeno[5,4-b]furan-8-yl]ethyl}propanamide
- SMILES
- CCC(=O)NCC[[email protected]@H]1CCC2=C1C1=C(OCC1)C=C2
Pharmacology
- Indication
For the treatment of insomnia characterized by difficulty with sleep onset.
- Structured Indications
- Pharmacodynamics
Ramelteon is the first selective melatonin agonist. It works by mimicking melatonin (MT), a naturally occuring hormone that is produced during the sleep period and thought to be responsible for the regulation of circadian rhythm underlying the normal sleep-wake cycle. Ramelteon has a high affinity for the MT1 and MT2 receptors. The MT1 and MT2 receptors are located in the brain's suprachiasmatic nuclei (SCN),which is known as the body's "master clock" because it regulates the 24-hour sleep-wake cycle. Ramelteon has an active metabolite that is less potent but circulates in higher concentrations than the parent compound. The metabolite also has weak affinity for the 5HT2b receptor.
- Mechanism of action
Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors, and lower selectivity for the MT3 receptor. Melatonin production is concurrent with nocturnal sleep, meaning that an increase in melatonin levels is related to the onset of self-reported sleepiness and an increase in sleep propensity. MT1 receptors are believed to be responsible for regulation of sleepiness and facilitation of sleep onset, and MT2 receptors are believed to mediate phase-shifting effects of melatonin on the circadian rhythm. While MT1 and MT2 receptors are associated with the sleep-wake cycle, MT3 has a completely different profile, and therefore is not likely to be involved in the sleep-wake cycle. Remelteon has no appreciable affinity for the gamma-aminobutyric acid (GABA) receptor complex or receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates.
Target Actions Organism AMelatonin receptor type 1A multitargetHuman AMelatonin receptor type 1B multitargetHuman - Absorption
Rapid, total absorption is at least 84%.
- Volume of distribution
- 73.6 L
- Protein binding
~82% (in human serum)
- Metabolism
Hepatic
- Route of elimination
Following oral administration of radiolabeled ramelteon, 84% of total radioactivity was excreted in urine and approximately 4% in feces, resulting in a mean recovery of 88%. Less than 0.1% of the dose was excreted in urine and feces as the parent compound.
- Half life
~1-2.6 hours
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Ramelteon is combined with 7-Nitroindazole. Experimental Abiraterone The serum concentration of Ramelteon can be increased when it is combined with Abiraterone. Approved Acepromazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Ramelteon is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Ramelteon is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Ramelteon is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Ramelteon is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Ramelteon. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Ramelteon is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Ramelteon is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Ramelteon is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Ramelteon. Approved, Illicit, Investigational Amiodarone The serum concentration of Ramelteon can be increased when it is combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Ramelteon is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ramelteon. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Ramelteon. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Ramelteon. Approved Amperozide The risk or severity of adverse effects can be increased when Ramelteon is combined with Amperozide. Experimental Apalutamide The serum concentration of Ramelteon can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Ramelteon can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ramelteon. Approved, Investigational Armodafinil The metabolism of Ramelteon can be decreased when combined with Armodafinil. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Ramelteon. Approved Atazanavir The serum concentration of Ramelteon can be increased when it is combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Ramelteon can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Ramelteon is combined with Azaperone. Investigational, Vet Approved Azelastine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azithromycin The metabolism of Ramelteon can be decreased when combined with Azithromycin. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Ramelteon. Approved Barbital The risk or severity of adverse effects can be increased when Ramelteon is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Ramelteon is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Benzocaine. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Ramelteon is combined with Benzyl alcohol. Approved Boceprevir The serum concentration of Ramelteon can be increased when it is combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Ramelteon can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Ramelteon can be decreased when it is combined with Bosentan. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Ramelteon is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Ramelteon. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Ramelteon is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Ramelteon is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Ramelteon. Approved Brotizolam The risk or severity of adverse effects can be increased when Ramelteon is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Bupivacaine. Approved, Investigational Buprenorphine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Ramelteon. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Ramelteon. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Ramelteon. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Ramelteon is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Ramelteon is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Ramelteon. Approved, Illicit, Vet Approved Caffeine The metabolism of Ramelteon can be decreased when combined with Caffeine. Approved Canertinib The risk or severity of adverse effects can be increased when Ramelteon is combined with Canertinib. Investigational Capecitabine The serum concentration of Ramelteon can be increased when it is combined with Capecitabine. Approved, Investigational Carbamazepine The metabolism of Ramelteon can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ramelteon. Approved Carfentanil The risk or severity of adverse effects can be increased when Ramelteon is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ramelteon. Approved Ceritinib The serum concentration of Ramelteon can be increased when it is combined with Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Ramelteon. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Ramelteon is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chloramphenicol The metabolism of Ramelteon can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ramelteon. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Ramelteon is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Ramelteon is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ramelteon. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Ramelteon is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ramelteon. Approved Cholecalciferol The metabolism of Ramelteon can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cimetidine The metabolism of Ramelteon can be decreased when combined with Cimetidine. Approved, Investigational Cinchocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Cinchocaine. Approved, Vet Approved Citalopram The metabolism of Ramelteon can be decreased when combined with Citalopram. Approved Clarithromycin The serum concentration of Ramelteon can be increased when it is combined with Clarithromycin. Approved Clemastine The metabolism of Ramelteon can be decreased when combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Ramelteon. Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Ramelteon. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Ramelteon is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Ramelteon is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Ramelteon is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Ramelteon. Approved Clopenthixol The risk or severity of adverse effects can be increased when Ramelteon is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Ramelteon. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Ramelteon is combined with Clothiapine. Experimental Clotrimazole The metabolism of Ramelteon can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Ramelteon. Approved Cobicistat The serum concentration of Ramelteon can be increased when it is combined with Cobicistat. Approved Cocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Ramelteon. Approved, Illicit Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Ramelteon. Approved, Investigational Crizotinib The metabolism of Ramelteon can be decreased when combined with Crizotinib. Approved Cyclizine The risk or severity of adverse effects can be increased when Ramelteon is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramelteon. Approved Cyclopropane The risk or severity of adverse effects can be increased when Ramelteon is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Ramelteon can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ramelteon. Approved Cyproterone acetate The serum concentration of Ramelteon can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabrafenib The serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Ramelteon is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Ramelteon is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Ramelteon is combined with Dapoxetine. Investigational Darunavir The serum concentration of Ramelteon can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Ramelteon can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Ramelteon can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The serum concentration of Ramelteon can be increased when it is combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Ramelteon is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Ramelteon. Approved Desipramine The risk or severity of adverse effects can be increased when Ramelteon is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Ramelteon. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Ramelteon is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Ramelteon is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of sedation and somnolence can be increased when Ramelteon is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Ramelteon is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Ramelteon is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Ramelteon is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Ramelteon is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Ramelteon. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Ramelteon is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Ramelteon is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ramelteon. Approved, Illicit Dihydroergotamine The metabolism of Ramelteon can be decreased when combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Ramelteon is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Ramelteon is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Ramelteon can be decreased when combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Ramelteon is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ramelteon. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ramelteon. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Ramelteon is combined with Doramectin. Vet Approved Dosulepin The serum concentration of Ramelteon can be increased when it is combined with Dosulepin. Approved Doxepin The risk or severity of adverse effects can be increased when Ramelteon is combined with Doxepin. Approved, Investigational Doxycycline The metabolism of Ramelteon can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Ramelteon is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved, Illicit Dronedarone The metabolism of Ramelteon can be decreased when combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Ramelteon is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Ramelteon is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Ramelteon is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Ramelteon is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Ramelteon is combined with Ecopipam. Investigational Efavirenz The metabolism of Ramelteon can be decreased when combined with Efavirenz. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Ramelteon is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Ramelteon is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Ramelteon. Approved, Investigational Enzalutamide The serum concentration of Ramelteon can be decreased when it is combined with Enzalutamide. Approved Erythromycin The metabolism of Ramelteon can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram. Approved, Investigational Eslicarbazepine acetate The metabolism of Ramelteon can be decreased when combined with Eslicarbazepine acetate. Approved Esomeprazole The metabolism of Ramelteon can be decreased when combined with Esomeprazole. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Ramelteon. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Ramelteon. Approved, Investigational Ethanol Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ramelteon is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramelteon. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Ramelteon. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Ramelteon is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Ramelteon is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ramelteon is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ramelteon is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Ramelteon is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Ramelteon is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Ramelteon is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Ramelteon is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Ramelteon is combined with Etorphine. Illicit, Vet Approved Etravirine The metabolism of Ramelteon can be decreased when combined with Etravirine. Approved Ezogabine The risk or severity of adverse effects can be increased when Ramelteon is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Ramelteon. Approved Fencamfamine The risk or severity of adverse effects can be increased when Ramelteon is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Ramelteon. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Ramelteon. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Ramelteon is combined with Flibanserin. Approved, Investigational Floxuridine The serum concentration of Ramelteon can be increased when it is combined with Floxuridine. Approved Fluanisone The risk or severity of adverse effects can be increased when Ramelteon is combined with Fluanisone. Experimental Fluconazole The serum concentration of Ramelteon can be increased when it is combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Ramelteon is combined with Fludiazepam. Approved, Illicit Flumazenil Flumazenil may decrease the sedative activities of Ramelteon. Approved Flunarizine The risk or severity of adverse effects can be increased when Ramelteon is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Ramelteon is combined with Flunitrazepam. Approved, Illicit Fluorouracil The serum concentration of Ramelteon can be increased when it is combined with Fluorouracil. Approved Fluoxetine The metabolism of Ramelteon can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Ramelteon. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Ramelteon. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Ramelteon. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Ramelteon is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ramelteon. Approved Fluvoxamine The serum concentration of Ramelteon can be increased when it is combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Ramelteon can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Ramelteon can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The metabolism of Ramelteon can be increased when combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Ramelteon is combined with Fospropofol. Approved, Illicit, Investigational Fusidic Acid The serum concentration of Ramelteon can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Ramelteon. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Ramelteon is combined with Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ramelteon. Approved, Illicit, Investigational Gemfibrozil The serum concentration of Ramelteon can be increased when it is combined with Gemfibrozil. Approved Gepirone The risk or severity of adverse effects can be increased when Ramelteon is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Ramelteon is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Ramelteon is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Ramelteon is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Ramelteon. Approved Halothane The risk or severity of adverse effects can be increased when Ramelteon is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Ramelteon is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Ramelteon is combined with Hexobarbital. Approved Hydrocodone Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ramelteon. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved Idelalisib The serum concentration of Ramelteon can be increased when it is combined with Idelalisib. Approved Iloperidone The risk or severity of adverse effects can be increased when Ramelteon is combined with Iloperidone. Approved Imatinib The metabolism of Ramelteon can be decreased when combined with Imatinib. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Ramelteon. Approved Indalpine The risk or severity of adverse effects can be increased when Ramelteon is combined with Indalpine. Investigational, Withdrawn Indinavir The serum concentration of Ramelteon can be increased when it is combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Ramelteon is combined with Indiplon. Investigational Isavuconazole The serum concentration of Ramelteon can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Ramelteon can be decreased when combined with Isavuconazonium. Approved, Investigational Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Ramelteon. Approved, Vet Approved Isoniazid The metabolism of Ramelteon can be decreased when combined with Isoniazid. Approved, Investigational Isradipine The metabolism of Ramelteon can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The serum concentration of Ramelteon can be increased when it is combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Ramelteon can be increased when it is combined with Ivacaftor. Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Ramelteon. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Ramelteon is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Ramelteon is combined with Ketobemidone. Approved, Investigational Ketoconazole The serum concentration of Ramelteon can be increased when it is combined with Ketoconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ramelteon. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Ramelteon is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Ramelteon is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Ramelteon is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Ramelteon is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Ramelteon is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Ramelteon is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Ramelteon. Approved Lidocaine The metabolism of Ramelteon can be decreased when combined with Lidocaine. Approved, Vet Approved Lithium The risk or severity of adverse effects can be increased when Ramelteon is combined with Lithium. Approved Lobeglitazone The metabolism of Ramelteon can be decreased when combined with Lobeglitazone. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Ramelteon is combined with Lofentanil. Illicit Lopinavir The serum concentration of Ramelteon can be increased when it is combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Ramelteon is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Ramelteon. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Ramelteon. Approved Lormetazepam The risk or severity of adverse effects can be increased when Ramelteon is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Ramelteon can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Ramelteon can be decreased when combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Ramelteon. Approved Luliconazole The serum concentration of Ramelteon can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Ramelteon can be decreased when it is combined with Lumacaftor. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Ramelteon can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Ramelteon. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Ramelteon is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Ramelteon. Approved Medazepam The risk or severity of adverse effects can be increased when Ramelteon is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Ramelteon is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Ramelteon is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Ramelteon is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Ramelteon. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Ramelteon is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Ramelteon. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ramelteon. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Ramelteon is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Ramelteon is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Ramelteon is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Ramelteon. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Ramelteon. Approved Methotrimeprazine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Ramelteon is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Ramelteon is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Ramelteon is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Ramelteon is combined with Methylphenobarbital. Approved Metyrosine Ramelteon may increase the sedative activities of Metyrosine. Approved Mexiletine The serum concentration of Ramelteon can be increased when it is combined with Mexiletine. Approved, Investigational Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Ramelteon. Approved, Illicit Midostaurin The serum concentration of Ramelteon can be increased when it is combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Ramelteon can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Ramelteon is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved, Investigational Mirtazapine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitotane The serum concentration of Ramelteon can be decreased when it is combined with Mitotane. Approved Moclobemide The metabolism of Ramelteon can be decreased when combined with Moclobemide. Approved, Investigational Modafinil The metabolism of Ramelteon can be decreased when combined with Modafinil. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Ramelteon is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Ramelteon. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Ramelteon. Approved Nefazodone The serum concentration of Ramelteon can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Ramelteon can be increased when it is combined with Nelfinavir. Approved Netupitant The serum concentration of Ramelteon can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Ramelteon can be increased when combined with Nevirapine. Approved Nicardipine The serum concentration of Ramelteon can be increased when it is combined with Nicardipine. Approved, Investigational Nilotinib The metabolism of Ramelteon can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Ramelteon. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ramelteon. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Ramelteon is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Ramelteon is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ramelteon. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon. Approved, Investigational Olaparib The metabolism of Ramelteon can be decreased when combined with Olaparib. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Ramelteon. Approved Omeprazole The metabolism of Ramelteon can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Ondansetron The risk or severity of adverse effects can be increased when Ramelteon is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Ramelteon is combined with Opium. Approved, Illicit Orphenadrine Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Ramelteon is combined with Osanetant. Investigational Osimertinib The serum concentration of Ramelteon can be increased when it is combined with Osimertinib. Approved Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Ramelteon. Approved Oxethazaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Oxethazaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Ramelteon is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Ramelteon. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ramelteon. Approved, Investigational, Vet Approved Palbociclib The serum concentration of Ramelteon can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Ramelteon. Approved Pantoprazole The metabolism of Ramelteon can be decreased when combined with Pantoprazole. Approved Paraldehyde Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine. Approved, Investigational Peginterferon alfa-2b The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b. Approved Penfluridol The risk or severity of adverse effects can be increased when Ramelteon is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Ramelteon. Approved, Vet Approved Pentobarbital The metabolism of Ramelteon can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved Perazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Ramelteon is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Ramelteon. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Ramelteon. Approved Phenazocine The risk or severity of adverse effects can be increased when Ramelteon is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Ramelteon is combined with Phenibut. Experimental Phenobarbital The metabolism of Ramelteon can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Ramelteon is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Ramelteon is combined with Phenoxyethanol. Approved Phenytoin The metabolism of Ramelteon can be increased when combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Ramelteon. Approved Pipamperone The risk or severity of adverse effects can be increased when Ramelteon is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Ramelteon is combined with Piritramide. Approved, Investigational Pitolisant The serum concentration of Ramelteon can be decreased when it is combined with Pitolisant. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Ramelteon is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Ramelteon is combined with Pomalidomide. Approved Posaconazole The serum concentration of Ramelteon can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole Ramelteon may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Ramelteon is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Ramelteon can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Prilocaine. Approved Primidone The metabolism of Ramelteon can be increased when combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramelteon. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Ramelteon. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Promethazine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Ramelteon is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Ramelteon. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Ramelteon. Approved Proxibarbal The risk or severity of adverse effects can be increased when Ramelteon is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Ramelteon is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Ramelteon. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Ramelteon. Approved Quinisocaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Ramelteon is combined with Raclopride. Investigational Ranolazine The metabolism of Ramelteon can be decreased when combined with Ranolazine. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Ramelteon. Approved Remoxipride The risk or severity of adverse effects can be increased when Ramelteon is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Ramelteon. Approved, Investigational Rifabutin The metabolism of Ramelteon can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Ramelteon can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Ramelteon can be increased when combined with Rifapentine. Approved, Investigational Rifaximin The metabolism of Ramelteon can be increased when combined with Rifaximin. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Ramelteon. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Ramelteon is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Ramelteon is combined with Romifidine. Vet Approved Ropinirole Ramelteon may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Ropivacaine. Approved Rotigotine Ramelteon may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Ramelteon can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ramelteon. Approved Saquinavir The serum concentration of Ramelteon can be increased when it is combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Ramelteon can be decreased when used in combination with Sarilumab. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Ramelteon. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Ramelteon. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Ramelteon is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Ramelteon is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The metabolism of Ramelteon can be decreased when combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ramelteon. Approved, Vet Approved Sildenafil The metabolism of Ramelteon can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Ramelteon can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Ramelteon can be increased when it is combined with Simeprevir. Approved Sodium oxybate Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. Approved St. John's Wort The serum concentration of Ramelteon can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Ramelteon can be increased when it is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon. Approved, Investigational Sulfadiazine The serum concentration of Ramelteon can be increased when it is combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfisoxazole The serum concentration of Ramelteon can be increased when it is combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Ramelteon is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Ramelteon is combined with Sultopride. Experimental Suvorexant Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Ramelteon is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. Approved Tasimelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Tasimelteon. Approved, Investigational Telaprevir The serum concentration of Ramelteon can be increased when it is combined with Telaprevir. Approved, Withdrawn Telithromycin The serum concentration of Ramelteon can be increased when it is combined with Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Ramelteon. Approved, Investigational Tenofovir disoproxil The metabolism of Ramelteon can be decreased when combined with Tenofovir disoproxil. Approved, Investigational Teriflunomide The serum concentration of Ramelteon can be decreased when it is combined with Teriflunomide. Approved Tetrabenazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Ramelteon is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrodotoxin. Investigational Thalidomide Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The metabolism of Ramelteon can be decreased when combined with Theophylline. Approved Thiamylal The risk or severity of adverse effects can be increased when Ramelteon is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Ramelteon is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Ramelteon. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Ramelteon. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Ramelteon. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Ramelteon is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Ramelteon can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Ramelteon is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Ramelteon is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Ramelteon. Approved, Investigational Tocilizumab The serum concentration of Ramelteon can be decreased when it is combined with Tocilizumab. Approved Tolbutamide The serum concentration of Ramelteon can be increased when it is combined with Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Ramelteon. Approved, Withdrawn Topiramate The metabolism of Ramelteon can be decreased when combined with Topiramate. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Ramelteon. Approved, Investigational Tranylcypromine The metabolism of Ramelteon can be decreased when combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Ramelteon is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Ramelteon. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Ramelteon is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Ramelteon is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ramelteon. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Ramelteon is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Ramelteon. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Ramelteon. Approved Valproic Acid The risk or severity of adverse effects can be increased when Ramelteon is combined with Valproic Acid. Approved, Investigational Vemurafenib The serum concentration of Ramelteon can be increased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Ramelteon can be decreased when combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Ramelteon is combined with Veralipride. Experimental Verapamil The metabolism of Ramelteon can be decreased when combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Ramelteon is combined with Vigabatrin. Approved Vinyl ether The risk or severity of adverse effects can be increased when Ramelteon is combined with Vinyl ether. Experimental Voriconazole The serum concentration of Ramelteon can be increased when it is combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Ramelteon is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Ramelteon is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Ramelteon is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Ramelteon. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ramelteon is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Ramelteon is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Ramelteon can be decreased when combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Ramelteon is combined with Zolazepam. Vet Approved Zolpidem Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Ramelteon. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Ramelteon. Approved Zotepine The risk or severity of adverse effects can be increased when Ramelteon is combined with Zotepine. Approved, Investigational, Withdrawn Zucapsaicin The metabolism of Ramelteon can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ramelteon. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Do not take with or immediately after a high-fat meal.
References
- Synthesis Reference
Vinod Kumar Kansal, Dhirenkumar N. Mistry, Sanjay L. Vasoya, "Intermediates and processes for the synthesis of Ramelteon." U.S. Patent US20080242877, issued October 02, 2008.
US20080242877- General References
- Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265]
- Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178]
- Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703]
- Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111]
- Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650]
- Simpson D, Curran MP: Ramelteon: a review of its use in insomnia. Drugs. 2008;68(13):1901-19. [PubMed:18729542]
- External Links
- Human Metabolome Database
- HMDB0015115
- PubChem Compound
- 208902
- PubChem Substance
- 46505923
- ChemSpider
- 181000
- BindingDB
- 50118470
- ChEBI
- 109549
- ChEMBL
- CHEMBL1218
- Therapeutic Targets Database
- DAP000070
- PharmGKB
- PA164744896
- IUPHAR
- 1356
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ramelteon
- ATC Codes
- N05CH02 — Ramelteon
- FDA label
- Download (2.36 MB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Takeda global research development center inc
- Packagers
- Bryant Ranch Prepack
- DispenseXpress Inc.
- Innoviant Pharmacy Inc.
- Physicians Total Care Inc.
- Rebel Distributors Corp.
- Southwood Pharmaceuticals
- Takeda Pharmaceutical Co. Ltd.
- Dosage forms
Form Route Strength Tablet, film coated Oral 8 mg/1 - Prices
Unit description Cost Unit Rozerem 8 mg tablet 5.17USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US6034239 No 1999-07-22 2019-07-22 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 2.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0164 mg/mL ALOGPS logP 3.03 ALOGPS logP 2.57 ChemAxon logS -4.2 ALOGPS pKa (Strongest Acidic) 15.82 ChemAxon pKa (Strongest Basic) -0.4 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 38.33 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 75.52 m3·mol-1 ChemAxon Polarizability 29.99 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9934 Caco-2 permeable + 0.5893 P-glycoprotein substrate Substrate 0.5211 P-glycoprotein inhibitor I Non-inhibitor 0.8548 P-glycoprotein inhibitor II Non-inhibitor 0.7877 Renal organic cation transporter Non-inhibitor 0.6381 CYP450 2C9 substrate Non-substrate 0.7876 CYP450 2D6 substrate Non-substrate 0.6392 CYP450 3A4 substrate Substrate 0.512 CYP450 1A2 substrate Inhibitor 0.7314 CYP450 2C9 inhibitor Non-inhibitor 0.6471 CYP450 2D6 inhibitor Non-inhibitor 0.5916 CYP450 2C19 inhibitor Inhibitor 0.8314 CYP450 3A4 inhibitor Non-inhibitor 0.9196 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7763 Ames test Non AMES toxic 0.7016 Carcinogenicity Non-carcinogens 0.8206 Biodegradation Ready biodegradable 0.6635 Rat acute toxicity 2.1034 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7898 hERG inhibition (predictor II) Inhibitor 0.5
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0nmi-2980000000-5ee1e7ec83e5c4578dfe
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Indanes
- Sub Class
- Not Available
- Direct Parent
- Indanes
- Alternative Parents
- Coumarans / Alkyl aryl ethers / Secondary carboxylic acid amides / Oxacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Indane / Coumaran / Alkyl aryl ether / Carboxamide group / Secondary carboxylic acid amide / Oxacycle / Organoheterocyclic compound / Ether / Carboxylic acid derivative / Hydrocarbon derivative
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Multitarget
- General Function
- Organic cyclic compound binding
- Specific Function
- High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
- Gene Name
- MTNR1A
- Uniprot ID
- P48039
- Uniprot Name
- Melatonin receptor type 1A
- Molecular Weight
- 39374.315 Da
References
- Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005 Feb;48(2):301-10. [PubMed:15695169]
- Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265]
- Greenblatt DJ, Harmatz JS, Karim A: Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007 Apr;47(4):485-96. [PubMed:17389558]
- Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650]
- Miyamoto M: Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett. 2006 Jul 24;402(3):201-4. Epub 2006 May 24. [PubMed:16730121]
- Authors unspecified: Ramelteon: TAK 375. Drugs R D. 2005;6(3):186-8. [PubMed:15869323]
- Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178]
- Miyamoto M: [A novel therapeutic drug: ramelteon]. Nihon Rinsho. 2009 Aug;67(8):1595-600. [PubMed:19768947]
- Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703]
- Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111]
- Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57. [PubMed:17015817]
- Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504. [PubMed:17803013]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Multitarget
- General Function
- Melatonin receptor activity
- Specific Function
- High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
- Gene Name
- MTNR1B
- Uniprot ID
- P49286
- Uniprot Name
- Melatonin receptor type 1B
- Molecular Weight
- 40187.895 Da
References
- Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005 Feb;48(2):301-10. [PubMed:15695169]
- Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265]
- Greenblatt DJ, Harmatz JS, Karim A: Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007 Apr;47(4):485-96. [PubMed:17389558]
- Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650]
- Miyamoto M: Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett. 2006 Jul 24;402(3):201-4. Epub 2006 May 24. [PubMed:16730121]
- Authors unspecified: Ramelteon: TAK 375. Drugs R D. 2005;6(3):186-8. [PubMed:15869323]
- Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178]
- Miyamoto M: [A novel therapeutic drug: ramelteon]. Nihon Rinsho. 2009 Aug;67(8):1595-600. [PubMed:19768947]
- Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703]
- Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111]
- Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57. [PubMed:17015817]
- Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504. [PubMed:17803013]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 02:05